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SUMMARY
Congenital hyperinsulinism (CHI) is a heterogenous disease caused by insulin secretion regulatory 
defects, being ABCC8/KCNJ11 the most commonly affected genes. Therapeutic options include 
diazoxide, somatostatin analogues and surgery, which is curative in focal CHI. We report the case 
of two siblings (born two years apart) that presented themselves with hypoketotic hyperinsulinemic 
persistent hypoglycemias during neonatal period. The diagnosis of diffuse CHI due to an ABCC8 
compound mutation (c.3576delG and c.742C>T) was concluded. They did not benefit from diazoxide 
therapy (or pancreatectomy performed in patient number 1) yet responded to somatostatin 
analogues. Patient number 1 developed various neurological deficits (including epilepsy), however 
patient number 2 experienced an entirely normal neurodevelopment. We believe this case shows 
how previous knowledge of the firstborn sibling’s disease contributed to a better and timelier medical 
care in patient number 2, which could potentially explain her better neurological outcome despite 
their same genotype. Arch Endocrinol Metab. 2018;62(5):560-5
INTRODUCTION
C ongenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycemia 
in infancy and it can potentially lead to permanent 
neurological damage (1,2). It is the result of a group 
of genetic disorders which can lead to severe and 
persistent hypoglycemia (3). Estimated incidence is 
1/50,000 live births (4). 
The disease is caused by mutations in various genes 
related to insulin secretion regulation (5), such as: 
ABCC8 (6), KCNJ11 (7), GCK (8), GLUD1 (9), 
HADH (10), SLC16A1 (11), HNF4A (12), HNF1A 
(13), UCP2 (14), HK1 (15) and PGM1 (16). The 
most common mutations affect ABCC8 and KCNJ11 
genes and lead to inactivation of the ATP-dependent 
potassium channel (KATP) subunits (SUR1 and Kir6.2 
respectively), resulting in unregulated insulin β-cell 
secretion (2,4,7,17).
Histologically the disease is characterized by 
Langerhans islet hyperplasia and can present as diffuse 
(18) or focal form (19), which is at least partially 
determined by the type of genetic defect (3). The two 
forms are clinically indistinguishable and the best way 
to differentiate is by performing a 18F-fluoro-L-DOPA 
positron emission tomography (PET) (20).
Pharmacotherapeutic options (3,21) include 
oral diazoxide as first line treatment and glucagon, 
somatostatin analogues and calcium channel blockers. 
In cases of focal hyperplasia, the treatment of choice is 
surgical removal of the affected tissue, which is usually 
curative (19). In diffuse forms that are unresponsive 
to medical therapy, near-total pancreatectomy can be 
an alternative, although risking complications such as 
diabetes (3).
We report the case of two siblings diagnosed 
in neonatal period with CHI who were found to 
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have the same genetic defect but different long-
term disease course. The previous knowledge of the 
firstborn sibling’s disease and how it responds to 
different therapeutic options led to a more appropriate 
therapeutic intervention in the second sibling, which we 
believe contributed decisively to a better neurological 
outcome, even with the same disease genotype. We 
believe this is a prime example of how a timely diagnosis 
and appropriate therapeutic strategy are determinant to 
a better clinical outcome.
CASE REPORT – PATIENT 1
An early term large-for-gestational age – birth weight: 
4,200 g (SDS +2.84) and APGAR 9/10 – male patient 
born to nonconsanguineous parents presented with 
severe and persistent hypoglycemia 36 hours after 
birth, with impaired consciousness level, hypotonia 
and bradycardia. This was his 28-year-old mothers first 
gestation and she developed gestational diabetes at the 
20th week (controlled with diet). There was no family 
history of hypoglycemic disorders. Starting on the 
fourth day of life, he required continuous infusion of 
concentration glucose (glucose infusion rate 8-10 mg/
kg/minute) to maintain normal blood glucose. 
Abdominal ultrasound and computed tomography 
did not identify any pancreatic abnormalities. 
Laboratory studies (Table 1) demonstrated very low 
levels of ketone bodies and free fatty acids in the 
presence of low glycemic values and inappropriately 
high insulin levels. Glucagon stimulation test yielded 
positive results – blood glucose increased 46.8 mg/
dL 30 minutes after glucagon administration. Genetic 
analyses, performed at 5 years of age, identified biallelic 
ABCC8 mutation – a frameshift mutation, c.3576delG, 
inherited from his mother and a nonsense mutation, 
c.742C>T, inherited from an unaffected father.
He was initially started on diazoxide (titrated to 
25 mg/kg/day) and later added hydrochlorothiazide. 
When he was 3 months old, he was submitted 
to exploratory abdominal surgery and near-total 
pancreatectomy (> 90%) due to persistent severe 
hypoglycemic episodes associated with seizures. 
Histology revealed diffuse pancreatic islets hyperplasia. 
Postoperatively, there were no improvements, so, at the 
age of two, he began gastrostomy continuous enteral 
feeding using complex carbohydrates and was switched 
to subcutaneous octreotide (20 µg/kg/day). 
Table 1. Laboratory findings at the time of hypoglycemia
Patient (Age) Patient 1  (1 month)
Patient 2  
(< 1 month)
Blood glucose (70-110 mg/dL) 28 12
Insulin (9.7-97.2 pmol/L) 64.6 110.4
C Peptide (0.30-1.42 nmol/L) 0.9 2.3
Hydroxybutyrate (< 300 µmol/L) Undetectable Undetectable
Free fatty acids (0.4-0.7 nmol/L) 0.33 0.43
Cortisol (137.9-689.7 nmol/L) 855.3 634.6
GH (< 20 µg/L) 5.4 11
Carnitines: 
Total (38-68 nmol/mL)
Free (27-49 nmol/mL)
Acilcarnitines (7-19 nmol/mL)
60
46
14
42
Lactate (0.6-2.3 mmol/L) 0.9 13.4
Pyruvate (80-160 µmoI/L) 67 54.5
Glutamic Acid (0.2-2.8 mg/dL) 0.77
Ammonia (10-65 µmol/L) 61 45
Urinary organic acids Negative Negative
Neurologic evaluation at 5 years of age demonstrated 
psychomotor development retardation, hemiparesis, 
dysesthesias and involuntary movements of the left arm. 
magnetic ressonance imaging (MRI) showed diffuse 
cerebral atrophy and a T2 hyperintensity of the medial 
temporal right lobe, suggestive of hypoglycemic sequelae 
(22). He was diagnosed with partial epilepsy and started 
on oxcarbazepine and, subsequently, valproic acid. 
The result of a continuous glucose monitoring 
performed at 13 years of age, while on medical therapy 
with octreotide and nifedipine, is shown in Figure 1A. By 
the age of 16 the patient exhibited improvement of his 
glycemic profile. Octreotide was switched to lanreotide 
(60 mg each 30 days) when he was 18 years old.
At the time of writing, the patient is 20 years old 
and remains without any recent hypoglycemic episodes 
although occasionally postprandially hyperglycemic 
(diabetes criteria not met). His BMI (body mass 
index) is 22.8 kg/m2, thus showing improvement since 
infancy (BMI > 97th percentile). He is 169 cm tall (SDS 
-1.15) (23) and target height was: 177.5 cm (SDS + 
0.25). IGF-1 and IGFBP-3 remained normal during 
all follow-up and pubertal development was adequate. 
He remains with slight neuropsychological deficits, 
without recent clinical epileptic activity. He is currently 
medically managed with lanreotide 60 mg each 30 
days, methylphenidate (started at 12 years of age due 
to attention deficit disorder) and carbamazepine.
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Figure 1. Results of both patients’ subcutaneous glucose monitoring: (A) Patient number 1’s 24-hour monitoring. Various periods of low blood glucose 
(40-60 mg/dL) were observed. (B) Patient number 2’s 6-days monitoring. Various periods of low blood glucose (40-60 mg/dL) were also registered in 
this case.
A
B
CASE REPORT – PATIENT 2
An early term – birth weight: 3,660 g (SDS +1.64) 
and APGAR 9/10 – female patient, sister of patient 
number 1 (born 2 years after him), presented with 
severe hypoglycemia (20 mgl/dL) one hour after birth. 
This was her mother’s second gestation and she, once 
more, developed gestational diabetes at the 20th week 
(managed with dietary measures). During her first days 
of life she required continuous infusion of glucose 
(glucose infusion rate 12 mg/kg/minute) to maintain 
euglycemia. 
Abdominal imaging and laboratory studies (Table 1), 
including glucagon simulation test, revealed similar 
results as patient number 1. Genetic analyses found the 
same compound mutation.
At the age of one month, she was started on 
diazoxide (12 mg/kg/day) and hydrochlorothiazide 
but showed no benefit. One month later diazoxide 
was switched to octreotide (20 mg/kg/day) and she 
was started on continuous gastrostomy enteral feeding. 
During infancy and adolescence, her hypoglycemic 
episodes became less frequent and less severe and there 
were no recorded hyperglycemic episodes – results of 
continuous glucose monitoring performed when she 
was 13 are shown in Figure 1B. She was switched to 
lanreotide (60 mg each 30 days) when she was 16.
Currently the patient is 18 years old and remains 
with occasional non-severe hypoglycemic episodes 
but is otherwise euglycemic. Her psychomotor and 
intellectual development remains normal. BMI values 
(BMI > 97th percentile) consistent with obesity were 
observed until she was 6 years old, however her present 
BMI is 22.6 kg/m2. Her final height is 160 cm (SDS 
-0.60) (23) and target height was: 165.4 cm (SDS+ 
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0.23). No GH/IGF axis abnormalities were found 
throughout follow-up. She is currently medically 
managed with lanreotide 60 mg each 28 days and is on 
a fractionated diet.
DISCUSSION
We describe the case of two siblings diagnosed 
with diazoxide-unresponsive CHI due to the same 
compound heterozygous ABCC8 mutation, yet 
different disease courses. 
In the presence of CHI, molecular biology plays 
an important role in providing a precise diagnosis and 
potentially guiding the pharmacotherapy (24). ABCC8 
gene mutation are the most commonly found defects in 
patients with CHI (6). Monoallelic ABCC8 mutations 
can cause both diazoxide-responsive and unresponsive 
CHI, however most biallelic mutations result in 
diazoxide-unresponsive form (25). 
Our patients presented with biallelic ABCC8 
mutations – c.3576delG and c.742C>T (already 
referred to in a Spanish genetic mutation database 
(17)). The former mutation, has only been described 
in heterozygosity and associated with the focal form 
of the disease (26,27). The latter has been associated 
with CHI both in homozygosity and heterozygosity 
presenting as histologically diffuse disease (28,29). 
Both mutations result in premature termination codons. 
Therefore, here we describe two cases of a novel (to 
the best of our knowledge) compound mutation that 
retains the histological features (diffuse disease based 
on pancreatic histology of patient number 1) of the 
c.742C>T mutation. Functional studies could confirm 
the resultant protein grade of dysfunction, as other 
authors have done in different compound mutations 
(25).
The first therapeutic approach usually consists 
of diazoxide. It inhibits pancreatic insulin secretion 
through interaction with the SUR1 subunit of the KATP 
and therefore in case of abnormalities in these proteins 
it might not be effective (3,21,30). Such is the case 
in ABCC8 mutations, making most of these patients 
diazoxide-unresponsive, as were these subjects. 
In patients with diazoxide-unresponsive CHI, 
somatostatin analogues, usually administered as 
subcutaneous injections, have shown some promise 
(3,21). They act on somatostatin receptors (SSTR2 
and SSTR5), inhibiting the secretion of various 
hormones, namely insulin. They have been used for 
over 20 years in the long-term control of diazoxide-
unresponsive forms of the disease (31), however they 
have yet to be officially approved for this purpose. 
In addition to its side-effect profile (which includes 
gastrointestinal symptoms, biliary lithiasis and rare 
cases of necrotizing enterocolitis), there is a risk of 
worsening hypoglycemia (due to suppression of GH 
and glucagon production) and tachyphylaxis (due to 
downregulation of somatostatin receptors), which can 
limit its long-term use (3,21). Octreotide is the drug 
with the most clinical experience, however in the last 
years there have been reports of successful lanreotide 
(long-acting somatostatin analogue) use (32). The 
presented cases represent how both octreotide 
and lanreotide can be effective in attaining blood 
glucose control both post (patient number 1) and 
pre-operatively (patient number 2) in case of diffuse 
diazoxide-unresponsive CHI. These drugs seemed 
better tolerated than diazoxide. 
Alternative pharmacotherapy options include 
nifedipine (a calcium channel blocker that has had 
mixed results (18)) and glucagon (used for short-term 
control of hypoglycemias (31)). Dietary treatment (21) 
can be sufficient in some cases and involves frequent 
glucose enriched oral feedings and continuous or 
frequent enteral feedings.
Surgical removal remains the best option in cases 
of an identifiable focal lesion associated with CHI 
– 94% can be rendered euglycemic at the time of 
discharge (33). In cases of medically refractory diffuse 
CHI, near-total pancreatectomy (95-98%) may be the 
only therapeutic option to cure or at least facilitate 
the medical management. The surgical outcome 
in case of diffuse CHI is highly variable: persistent 
hypoglycemia in about 50% of patients and diabetes 
in 20%, however most improve their glycemic control 
(3). This option must be carefully weighted also due 
to its potential complications (namely diabetes and 
exocrine pancreatic insufficiency (34)) and the fact that 
spontaneous remission can be observed in some cases 
(31). Regarding our cases, near-total pancreatectomy 
was performed in patient number 1 due to the severity 
and neurological repercussions of his hypoglycemic 
events and the lack of alternative pharmacotherapeutic 
options, even though by that time there was not a 
molecular diagnosis nor any other data to estimate the 
pancreatic extent of the disease (PET was not available 
and there were no macroscopic pancreatic lesions on 
surgical exploration). There was no clinical benefit 
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post-operatively and this contributed to the decision to 
withhold surgery in patient number 2 – also given the 
new-found knowledge of the extent of CHI (diffuse 
involvement based on patient number 1 pancreatic 
histology) associated with this mutation. 
There have been reports of patients with CHI due 
to HNF4A (35) and HNF1A mutations (36) who 
present initially with hyperinsulinemic hypoglycemia 
and develop maturity-onset diabetes of the young 
type (MODY) later in life. ABCC8 mutations have 
been implied in cases of neonatal diabetes (frequently 
transient), MODY (37) and there are reports of 
hyperinsulinemic hypoglycemic disorder in early life 
progressing to insulinopenic diabetes later on (38). 
Regarding our cases, patient number 1 continues 
to record periods of post prandial hyperglycemia, 
although diabetes has been excluded using oral glucose 
tolerance test and glycated hemoglobin measurement. 
This phenomenon is most likely a complication of near-
total pancreatectomy rather than another feature of her 
disease/genotype. Additional support to this hypothesis 
is presented by the fact that there were no hyperglycemic 
episodes recorded to date in the case of patient number 
2, with the same disease genotype. Nevertheless, given 
these cases concern a new compound mutation, the 
risk of progression to diabetes in adulthood is largely 
unknown and should not be disregarded. 
An interesting finding is the fact that the mother 
developed gestational diabetes in both pregnancies, 
although hyperglycemia did not persist after deliveries. 
It has already been established that maternal 
hyperglycemia can induce fetal hyperinsulinemia and be 
responsible for macrosomia and neonatal hypoglycemia 
(39). Nevertheless, no link has ever been implied 
between maternal hyperglycemia and the presence 
of insulin regulatory gene mutations (the mother 
was found to be carrier of the ABCC8 c3576delG 
mutation). 
Prolonged and severe hypoglycemias expose patients 
to a poor neurological outcome and, indeed, some 
series report neurodevelopment delay issues in as much 
as 30% of CHI patients (18). This risk may be higher 
in cases of neonatal onset and diazoxide-unresponsive 
CHI (3). Some MRI brain injury patterns have been 
identified (22), such as cerebral cortex T2 hyperintense 
lesions while sparing cerebellum, brainstem, and 
thalamus – this was the case of patient number 1. 
Taking this into account, the better neurodevelopment 
observed in patient number 2 can probably be linked 
to a more rapid and appropriate treatment approach 
due to the previous knowledge of her sibling’s disease. 
In particular, octreotide was initiated when she was 2 
months old while her brother only started at 2 years 
of age, which probably led to a lesser frequency and 
severity of hypoglycemic episodes during her infancy 
and could explain her better neurological outcome. 
In conclusion, we report the case of two siblings with 
diazoxide-resistant CHI caused by the same compound 
ABCC8 mutation. Their therapeutic management 
had some differences and this could offer a potential 
explanation for the distinct neurological outcome, 
despite the same genetic basis for the disease. This case 
highlights the importance of the first siblings index case 
clinical and molecular diagnosis and how it seemed to 
contribute to a better disease knowledge and medical 
care in patient number 2, ultimately resulting in a 
better outcome in spite of the same disease genotype.
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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